Oncotarget

Research Papers:

Androgen deprivation therapy prevents bladder cancer recurrence

Koji Izumi _, Masataka Taguri, Hiroshi Miyamoto, Yoshinori Hara, Takeshi Kishida, Kimio Chiba, Tetsuo Murai, Kotaro Hirai, Kotaro Suzuki, Kiyoshi Fujinami, Teiichiro Ueki, Koichi Udagawa, Kazuo Kitami, Masatoshi Moriyama, Yasuhide Miyoshi, Futoshi Tsuchiya, Ichiro Ikeda, Kazuki Kobayashi, Maho Sato, Satoshi Morita, Kazumi Noguchi and Hiroji Uemura

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:12665-12674. https://doi.org/10.18632/oncotarget.2851

Metrics: PDF 2182 views  |   HTML 3165 views  |   ?  


Abstract

Koji Izumi1, Masataka Taguri2, Hiroshi Miyamoto3, Yoshinori Hara4, Takeshi Kishida5, Kimio Chiba6, Tetsuo Murai7, Kotaro Hirai8, Kotaro Suzuki9, Kiyoshi Fujinami10, Teiichiro Ueki11, Koichi Udagawa12, Kazuo Kitami13, Masatoshi Moriyama14, Yasuhide Miyoshi15, Futoshi Tsuchiya16, Ichiro Ikeda17, Kazuki Kobayashi18, Maho Sato2, Satoshi Morita19, Kazumi Noguchi15, Hiroji Uemura1

1Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

2Department of Biostatistics and Epidemiology, Yokohama City University Medical Center, Yokohama, Japan

3Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

4Department of Urology, Odawara Municipal Hospital, Odawara, Japan

5Department of Urology, Kanagawa Cancer Center, Yokohama, Japan

6Department of Urology, Kawasaki Municipal Ida Hospital, Kawasaki, Japan

7Department of Urology, International Goodwill Hospital, Yokohama, Japan

8Department of Urology, Sagamihara National Hospital, Sagamihara, Japan

9Department of Urology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

10Department of Urology, Chigasaki Municipal Hospital, Chigasaki, Japan

11Department of Urology, Japanese Red Cross Hadano Hospital, Hadano, Japan

12Department of Urology, Hiratsuka Kyousai Hospital, Hiratsuka, Japan

13Department of Urology, Fujisawa City Hospital, Fujisawa, Japan

14Department of Urology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan

15Department of Urology, Yokohama City University Medical Center, Yokohama, Japan

16Department of Urology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan

17Department of Urology, Yokohama Minami Kyousai Hospital, Yokohama, Japan

18Department of Urology, Yokosuka Kyousai Hospital, Yokosuka, Japan

19Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan

Correspondence to:

Hiroji Uemura, e-mail: hu0428@med.yokohama-cu.ac.jp

Keywords: Bladder cancer, recurrence, androgen, androgen deprivation therapy

Received: November 05, 2014     Accepted: December 03, 2014     Published: December 24, 2014

ABSTRACT

Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients.

We retrospectively reviewed 20,328 patients with PC diagnosed during 1991–2013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort.

With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17–0.49) for BC recurrence.

This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2851